Lennar Corporation, together with its subsidiaries, operates as a homebuilder primarily under the Lennar brand in the United States. It operates through Homebuilding East, Homebuilding Central, Homebuilding Texas, Homebuilding West, Financial Services, Multifamily, and Lennar Other segments. The company's homebuilding operations include the construction and sale of single-family attached and detached homes, as well as the purchase, development, and sale of residential land; and development, construction, and management of multifamily rental properties. It also offers residential mortgage financing, title, insurance, and closing services for home buyers and others, as well as originates and sells securitization commercial mortgage loans. In addition, the company is involved in the fund investment activity. It primarily serves first-time, move-up, active adult, and luxury homebuyers. The company was founded in 1954 and is based in Miami, Florida.

Lennar Corporation Class A

Ellenbarrie Industrial Gases Limited ( ($IN:ELLEN) ) has provided an announcement. Ellenbarrie Industrial Gases Limited has announced the closure o...

Ellenbarrie Industrial Gases to Close Trading Window Ahead of Q3 FY2026 Results

Barclays analyst Matthew Bouley maintained a Sell rating on Lennar today and set a price target of $88.00. Bouley covers the Industrials sector, fo...

Barclays Remains a Sell on Lennar (LEN)

In a report released today, Sam Reid from Wells Fargo maintained a Hold rating on Lennar, with a price target of $125.00. Reid covers the Consumer ...

Wells Fargo Reaffirms Their Hold Rating on Lennar (LEN)

Markets End the Week Lower as AI Stocks Slide and Gold Hits a Record U.S. stocks ended the week lower as investors pulled back from mega-cap techno...

The Week That Was, The Week Ahead: Macro & Markets, Dec. 14

LENZ Therapeutics ( ($LENZ) ) just unveiled an announcement. LENZ Therapeutics, Inc. addressed a recent adverse event report submitted to the FDA’s...

LENZ Therapeutics Responds to FDA Adverse Event Report

Lennar received a Sell rating and a $98.00 price target from Barclays analyst Matthew Bouley today. Bouley covers the Industrials sector, focusing ...

Barclays downgrades Lennar (LEN) to a Sell

Citi analyst Yigal Nochomovitz maintained a Buy rating on LENZ Therapeutics on December 4 and set a price target of $52.00. The company’s shares cl...

LENZ Therapeutics (LENZ) Receives a Buy from Citi

In a report released on December 3, Ben Davis from RBC Capital reiterated a Buy rating on Glencore, with a price target of p320.00. The company’s s...

RBC Capital Sticks to Their Buy Rating for Glencore (GLEN)

Analysts are intrested in these 5 stocks: ( ($LEN) ), ( ($PFE) ), ( ($NET) ), ( ($SYM) ) and ( ($WDAY) ). Here is a breakdown of their recent


Lennar, Pfizer, Cloudflare, Symbotic, Workday: Trending by Analysts

In a report released today, Ephrem Ravi from Citi maintained a Buy rating on Glencore, with a price target of £4.40. Ravi covers the Basic Material...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LEN	$105.09	+0.33%	1.40M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LEN	$105.09	+0.3%	1.40M
3
4
5
6

LEN

LEN

Get Lennar Corporation Class A Data in Excel

Get Lennar Corporation Class A Data in Excel